HC Wainwright Analysts Boost Earnings Estimates for MLYS

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) – Stock analysts at HC Wainwright lifted their Q3 2026 EPS estimates for Mineralys Therapeutics in a research note issued to investors on Wednesday, August 12th. HC Wainwright analyst M. Caufield now forecasts that the company will earn ($0.56) per share for the quarter, up from their previous forecast of ($0.61). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Mineralys Therapeutics’ current full-year earnings is ($2.30) per share. HC Wainwright also issued estimates for Mineralys Therapeutics’ Q4 2026 earnings at ($0.60) EPS, FY2026 earnings at ($4.47) EPS, FY2027 earnings at ($3.78) EPS, FY2028 earnings at ($2.27) EPS and FY2029 earnings at $0.42 EPS.

Mineralys Therapeutics (NASDAQ:MLYS) last issued its earnings results on Wednesday, August 12th. The company reported ($2.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($2.30).

Several other equities analysts have also weighed in on the stock. TD Cowen began coverage on shares of Mineralys Therapeutics in a research report on Monday, April 27th. They set a “buy” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Friday, July 17th. Jefferies Financial Group reissued a “hold” rating on shares of Mineralys Therapeutics in a research report on Monday, June 1st. Finally, Wall Street Zen lowered Mineralys Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Mineralys Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $49.33.

Mineralys Therapeutics Trading Down 3.5%

Shares of NASDAQ:MLYS opened at $26.09 on Friday. The firm has a market cap of $2.31 billion, a P/E ratio of -6.15 and a beta of 0.68. Mineralys Therapeutics has a twelve month low of $13.40 and a twelve month high of $47.65. The company has a 50 day moving average of $26.44 and a 200-day moving average of $27.55.

Institutional Investors Weigh In On Mineralys Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Jennison Associates LLC boosted its stake in Mineralys Therapeutics by 234.4% during the 4th quarter. Jennison Associates LLC now owns 1,258,653 shares of the company’s stock valued at $45,677,000 after purchasing an additional 882,307 shares during the period. TimesSquare Capital Management LLC bought a new position in Mineralys Therapeutics in the 4th quarter worth approximately $13,794,000. UBS Group AG lifted its holdings in shares of Mineralys Therapeutics by 124.9% during the fourth quarter. UBS Group AG now owns 201,280 shares of the company’s stock worth $7,304,000 after buying an additional 111,776 shares during the last quarter. Artia Global Partners LP boosted its position in shares of Mineralys Therapeutics by 143.5% in the fourth quarter. Artia Global Partners LP now owns 137,800 shares of the company’s stock valued at $5,001,000 after acquiring an additional 81,200 shares during the period. Finally, Profund Advisors LLC boosted its position in shares of Mineralys Therapeutics by 548.1% in the fourth quarter. Profund Advisors LLC now owns 47,024 shares of the company’s stock valued at $1,707,000 after acquiring an additional 39,768 shares during the period. 84.46% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Jon Congleton sold 75,000 shares of the company’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $26.14, for a total transaction of $1,960,500.00. Following the completion of the sale, the chief executive officer directly owned 614,321 shares of the company’s stock, valued at approximately $16,058,350.94. This represents a 10.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Eric Warren sold 104,124 shares of the firm’s stock in a transaction on Friday, June 26th. The shares were sold at an average price of $25.90, for a total transaction of $2,696,811.60. Following the completion of the transaction, the insider owned 38,400 shares in the company, valued at $994,560. The trade was a 73.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 217,313 shares of company stock worth $5,624,488. 18.94% of the stock is currently owned by company insiders.

Mineralys Therapeutics News Summary

Here are the key news stories impacting Mineralys Therapeutics this week:

• Positive Sentiment: FDA decision and launch preparations remain on track: Mineralys reiterated a December 22, 2026 PDUFA date for lorundrostat, its investigational hypertension treatment, and said commercial launch preparations are progressing. Launch readiness and cash runway
• Positive Sentiment: Cash runway provides financial flexibility: Management said its cash position should fund operations into 2028, reducing near-term financing risk as the company advances toward a potential launch. The company also highlighted actions intended to improve lorundrostat’s long-term economics. Second-quarter earnings call highlights
• Positive Sentiment: Near-term EPS estimates improved: HC Wainwright raised its Q3 2026 EPS forecast to a loss of $0.56 from $0.61 and its Q4 forecast to a loss of $0.60 from $0.70, while retaining its Buy rating.
• Neutral Sentiment: New chief medical officer appointed: Mineralys granted Dr. Terry Ferguson inducement awards covering 135,000 stock options and 102,400 restricted stock units. The appointment strengthens late-stage development leadership, although the equity awards create potential dilution. Inducement award announcement
• Negative Sentiment: Large quarterly earnings miss: Mineralys reported a second-quarter loss of $2.85 per share, far worse than the $0.55 consensus loss, increasing concerns about spending and execution even though the company remains pre-commercial. Second-quarter earnings call transcript
• Negative Sentiment: Long-term earnings outlook was reduced: HC Wainwright cut its FY2026 EPS estimate to a $4.47 loss from $2.33, FY2027 to a $3.78 loss from $2.84, FY2028 to a $2.27 loss from $1.52, and FY2029 profit to $0.42 from $0.92. It also lowered FY2030 profit expectations to $3.41 from $3.73.
• Negative Sentiment: Insider selling adds a modest cautionary signal: David Malcom Rodman sold 2,170 shares worth approximately $58,785 under a pre-arranged Rule 10b5-1 plan, reducing his holdings by 4.05%. Insider sale disclosure

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.